Table 1.
Treatment | TST min | Sleep efficiency | Night TST (100%) |
WASO (%) | Wake (%) | Sleep onset to REM (min) | Daytime sleep (%) | ||
---|---|---|---|---|---|---|---|---|---|
Stage 1–2 | SWS | REM | |||||||
Control mean | 595.8 | 83.0 | 54.5 | 23.8 | 22.0 | 14.2 | 17.0 | 49.6 | 1.6 |
SEM | 7.0 | 2.0 | 4.0 | 3.0 | 1.0 | 2.0 | 1.5 | 10.0 | 1.0 |
MPTP mean | 410.5*** | 57.1*** | 67.4** | 12.5*** | 17.3*** | 40.0*** | 42.9*** | 101.5* | 12.8*** |
SEM | 25.0 | 3.6 | 3.2 | 2.8 | 1.7 | 4.9 | 3.8 | 10.1 | 2.7 |
l-Dopa mean | 452.9* | 63.1* | 64.9 | 13.2 | 19.1* | 32.4 | 37.0* | 98.8 | 5.8** |
SEM | 18.1 | 2.6 | 4.1 | 3.4 | 1.3 | 3.7 | 2.6 | 10.8 | 1.6 |
PPN 3w mean | 489.4 | 69.3 | 66.2 | 14.2 | 18.2 | 35.8 | 30.7 | 127.0 | 4.7 |
SEM | 36 | 6.5 | 4.4 | 2.2 | 3.5 | 14.9 | 6.5 | 15.1 | 1.6 |
aMean values of sleep parameters were calculated in 4 macaques in the control state, after MPTP intoxication, and then after l-dopa treatment, in 3 macaques 3 weeks (3w) after a unilateral PPN lesion and in one of these macaques after a second PPN lesion in the other hemisphere. MPTP values were compared with control values, and l-dopa values with MPTP values. Level of significance was given only in the case of statistical significance for each individual.
*p < 0.05;
**p < 0.01;
***p < 0.001: Kruskal–Wallis test followed by Mann–Whitney U test in the event of statistically significant differences.